---
layout: post
title: New Drug Approvals 2011 - Pt. XXV crizotinib (Xalkori®)
date: '2011-08-28T15:15:00.005+01:00'
author: Bissan Al-Lazikani
tags:
- 2011 New Drugs
- Small Molecule Drugs
- Kinase inhibitor
modified_time: '2011-08-30T09:51:43.737+01:00'
thumbnail: http://4.bp.blogspot.com/-AmnOXcCpmo4/TliERp5LHNI/AAAAAAAAAFs/XdY5DxAiGg0/s72-c/Xalkori.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2078426259190811922
blogger_orig_url: http://chembl.blogspot.com/2011/08/new-drug-approvals-2011-pt-xxv_28.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://4.bp.blogspot.com/-AmnOXcCpmo4/TliERp5LHNI/AAAAAAAAAFs/XdY5DxAiGg0/s1600/Xalkori.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="74" src="http://4.bp.blogspot.com/-AmnOXcCpmo4/TliERp5LHNI/AAAAAAAAAFs/XdY5DxAiGg0/s400/Xalkori.png" width="170" /></a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><br />
<center> <img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,1,1,0,0,1,0,0" width="400" /> </center> <br />
<div class="separator" style="clear: both; text-align: -webkit-auto;"><br />
</div><div class="separator" style="clear: both; text-align: center;">ATCC: L01XE15</div><div class="separator" style="clear: both; text-align: center;">Wikipedia: <a href="http://en.wikipedia.org/wiki/Crizotinib">Crizotinib</a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><span class="Apple-style-span" style="font-family: inherit;">On the August 26th 2011, the FDA approved crizotinib (trade name:<a href="http://www.trademarkia.com/trademarks-search.aspx?tn=xalkori">Xalkori</a>® Research code: PF-02341066), an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (<a href="http://en.wikipedia.org/wiki/NSCLC">NSCLC</a>) that is ALK-positive as detected by an approved FDA-approved test. </span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">Non-small cell lung carcinomas (NSCLC) are cancers of the epithelial cells in the lung and describe all types of lung carcinomas other than small cell carcinomas. NSCLCs make up 88% of all lung carcinomas (see Cancer Research UK <a href="http://cancerhelp.cancerresearchuk.org/type/lung-cancer/about/types-of-lung-cancer">pages</a>) and comprise genetically distinct classes of cancer, the most common are: Lung adenocarcinoma, large cell carcinoma and squamous cell carcinoma.  Across the NSCLC types, some tumors harbour an ALK fusion protein. The EML4-ALK fusion gene has been shown to be affect the outcome of drug response and cells show resistance to EGFR inhibitors.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />


<span class="Apple-style-span" style="font-family: inherit;">C<span class="Apple-style-span">rizotinib is an orally-dosed receptor tyrosine kinase inhibitor with significant activity against <a href="http://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase">ALK</a>&nbsp;(UniProt:<a href="http://www.uniprot.org/uniprot/Q9UM73">Q9UM73</a></span><span class="Apple-style-span">, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL4247">CHEMBL4247</a>), <a href="http://en.wikipedia.org/wiki/HGFR">HGFR</a> (also known as c-Met) (Uniprot:<a href="http://www.uniprot.org/uniprot/P08581">P08581</a> <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL3717">CHEMBL3717</a>) and RON (UniProt:<a href="http://www.uniprot.org/uniprot/Q04912">Q04912</a>, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2689">CHEMBL2689</a>), and it is the first in class agent against any of these targets. However, ALK is the main targeted protein in these ALK-dependent, EGFR inhibitor resistant cancers. 

ALK is a trans-membrane receptor tyrosine kinase with the regulatory domains being extracellular and the kinase catalytic domain intracellular. The amino-acid sequence of the full wild type kinase is:
<PRE>

>ALK (full length wild type, kinase domain in red)
MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVV
PSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEA
RTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQ
GEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDY
FTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQ
MDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGR
YIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFF
ALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYC
NFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFP
APIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPL
LDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNP
NKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPL
KGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGE
DACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLII
AAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGA
TGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFIS
PLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVS
CIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKL
SKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKN<font color=red>ITLIRGLGHGAFGEVYEGQVSGMPN
DPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMA
GGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCP
GPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLW
EIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIIL
ERIEYCTQDP</font>DVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAA
PPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPT
SLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPS
SLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP
</PRE>
The ELM4-ALK translocation protduces a chimeric protein with the N-terminal part of ELM4 and the catalytic region of ALK. This chimeria is constitutively active causing unregulated proliferation (<a href="http://www.ncbi.nlm.nih.gov/pubmed/17625570">Soda et al</a>)
<P>

The structure of ALK in complex with crizotinib has been determined (2XP2)<br>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-AKivf4U_kzs/TlykTorInxI/AAAAAAAAAF0/CEIL1In6KGA/s1600/ALK.png" imageanchor="1" style="margin-left:1em; margin-right:1em"><img border="0" height="400" width="396" src="http://1.bp.blogspot.com/-AKivf4U_kzs/TlykTorInxI/AAAAAAAAAF0/CEIL1In6KGA/s400/ALK.png" /></a></div>

<P>

ALK and other proteins inhibited by crizotinib are members of the large protein kinase family, the target of several other recently approved drugs - with the approval of crizotinib there are now 12 US approved small molecule protein kinase inhibitors (</span><a href="http://en.wikipedia.org/wiki/Imatinib">Imatinib</a>, <a href="http://en.wikipedia.org/wiki/Gefitinib">Gefitinib</a>, <a href="http://en.wikipedia.org/wiki/Erlotinib">Erlotinib</a>, <a href="http://en.wikipedia.org/wiki/Sorafenib">Sorafenib</a>,&nbsp;<a href="http://en.wikipedia.org/wiki/Dasatinib">Dasatinib</a>, <a href="http://en.wikipedia.org/wiki/Sunitinib">Sunitinib</a>, <a href="http://en.wikipedia.org/wiki/Nilotinib">Nilotinib</a>, <a href="http://en.wikipedia.org/wiki/Lapatinib">Lapatinib</a>,&nbsp;<a href="http://en.wikipedia.org/wiki/Pazopanib">Pazopanib</a>, <a href="http://en.wikipedia.org/wiki/Vandetanib">Vandetanib</a> &amp; <a href="http://en.wikipedia.org/wiki/Vemurafenib">Vemurafenib</a>), with over an additional 300 protein kinase inhibitors that have progressed to clinical trials.</span><br />
<span class="Apple-style-span" style="font-family: TimesNewRoman; font-size: 16px;"><br />
</span><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://4.bp.blogspot.com/-7kXgDO7UcuM/TlpFueIshuI/AAAAAAAABR8/bF3_eoN6h5g/s1600/crizotinib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-7kXgDO7UcuM/TlpFueIshuI/AAAAAAAABR8/bF3_eoN6h5g/s1600/crizotinib.png" /></a></div><span class="Apple-style-span" style="font-family: TimesNewRoman; font-size: 16px;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span">The molecular formula for crizotinib is C21H22Cl2FN5O, with a molecular weight of</span><span class="Apple-style-span">&nbsp;450.34 Da. (IUPAC: (R)-3-[1-(2,6- Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine, Canonical SMILES<span class="Apple-style-span" style="font-family: inherit;">:</span></span></span><span class="Apple-style-span" style="font-family: inherit;">CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N, InChI key:<span class="Apple-style-span" style="font-family: inherit;">KTEIFNKAUNYNJU-GFCCVEGCSA-N,</span><span class="Apple-style-span" style="color: #666666;"> C</span></span><span class="Apple-style-span">hemspider:<a href="http://www.chemspider.com/Chemical-Structure.9801307.html">9801307</a>, PubChem:<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11626560">11626560</a>). It is fully rule of five compliant.&nbsp;</span><span class="Apple-style-span">Crizotinib has two ionizable centres with a pKa of 9.4 (for the piperidinium cation) and 5.6 (for the pyridinium cation). The experimental logD (octanol/water) at pH 7.4 is 1.65. Crizotinib is a chirally pure, synthetic small molecule drug.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span">Standard dosing of Crizotinib is 250mg twice daily (so a 500 mg daily dose - equivalent to 1,110 umol). The mean absolute bioavailability of Crizotinib is 43% following the administration of a single 250 mg oral dose.</span>&nbsp;<span class="Apple-style-span">Crizotinib shows a median time to achieve peak concentration (Tmax) of 4 to 6 hours. Following crizotinib 250 mg twice daily dosing, steady state drug levels are reached within 15 days.&nbsp;</span>The volume of distribution (Vss) of crizotinib is 1,772 L (following intravenous administration of a 50 mg dose) - so crizotinib is extensively distribution into tissues from the plasma; plasma protein binding (ppb) is 91%, and it is a substrate for&nbsp;&nbsp;P-glycoprotein (P-gp).</span><br />
<div class="column"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">Crizotinib is predominantly metabolized by CYP3A4 and CYP3A5. The primary metabolic pathways in humans are oxidation of the piperidine ring to crizotinib lactam and O-dealkylation, followed by subsequent Phase 2 conjugation of O-dealkylated metabolites. Crizotinib is an inhibitor of CYP3A. The mean apparent plasma terminal half-life of crizotinib iss 42 hours, with an&nbsp;apparent clearance (CL/F) of&nbsp;100 L/hr following a single dose, or 60 L/hr for the 250 mg twice daily standard dosing - this is most likely due to inhibition of CYP3A4/5.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">Crizotinib is marketed by <a href="http://www.pfizer.com/">Pfizer</a>, full prescribing information can be found <a href="http://www.pfizerpro.com/resources/minisites/xalkori_home/aval/docs/CRI_pi.pdf">here</a>.</span></div>